Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.58 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.52 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.48 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.48 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.48 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.47 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.47 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.46 |
| ▸ | PNMT | P11086 | 1/20 | 0.45 |
| ▸ | IDO1 | P14902 | 1/20 | 0.45 |
| ▸ | BID | P55957 | 3/20 | 0.45 |
| ▸ | MCL1 | Q07820 | 3/20 | 0.45 |
| ▸ | BCL2L1 | Q07817 | 2/20 | 0.45 |
| ▸ | BAK1 | Q16611 | 2/20 | 0.45 |
| ▸ | KAT8 | Q9H7Z6 | 2/20 | 0.45 |
| ▸ | PPARG | P37231 | 1/20 | 0.45 |
| ▸ | PPARA | Q07869 | 1/20 | 0.45 |
| ▸ | EP300 | Q09472 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5271594 | 1.00 | LIPG (0.58) | LIPGTAAR1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL28250901 | 1.00 | LIPG (0.58) | LIPGTAAR1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL196431 | 1.00 | LIPG (0.58) | LIPGTAAR1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL5598971 | 1.00 | LIPG (0.58) | LIPGTAAR1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL5599139 | 1.00 | LIPG (0.58) | LIPGTAAR1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL3694247 | 1.00 | LIPG (0.58) | LIPGTAAR1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL19391066 | 1.00 | LIPG (0.58) | LIPGTAAR1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL11658176 | 1.00 | LIPG (0.58) | LIPGTAAR1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL31444780 | 1.00 | LIPG (0.58) | LIPGTAAR1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL31445158 | 0.98 | LIPG (0.56) | LIPGTAAR1SLC6A2SLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024063116-A1 | ORGANIC LIGHT-EMITTING ELEMENT | キヤノン株式会社 | 2024-03-28 | — | — | WO | disclosed |
| US-20220177476-A1 | Crystal Forms of (S)-4-(8-amino-3-(1-(but-2-ynoyl)-pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-n-(pyridin-2-yl)benzamide | ACERTA PHARMA BV (NL) | 2022-06-09 | — | — | US | disclosed |
| US-10640509-B2 | Pharmaceutical composition comprising a crystal form of (S)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-N-(pyridin-2-yl)benzamide for treating diffuse large B-cell lymphoma | ACERTA PHARMA B.V. (NL) | 2020-05-05 | — | — | US | disclosed |
| US-20190337949-A1 | Solid Forms and Formulations of Imidazopyrazine Compound | ACERTA PHARMA B.V. (NL) | 2019-11-07 | — | — | US | disclosed |
| US-9796721-B2 | Crystal forms of (S)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-N-(pyridin-2-yl)benzamide | ACERTA PHARMA B.V. (NL) | 2017-10-24 | — | — | US | disclosed |
| US-20170029428-A1 | Solid Forms and Formulations of Imidazopyrazine Compound | ACERTA PHARMA B.V. (NL) | 2017-02-02 | — | — | US | disclosed |
| US-7375250-B2 | Aminoanthryl derivative substitution compound and organic electroluminescence device using the same | CANON KABUSHIKI KAISHA (JP) | 2008-05-20 | — | — | US | disclosed |
| US-7358409-B2 | Substituted anthryl derivative and electroluminescence device using the same | CANON KABUSHIKI KAISHA (JP) | 2008-04-15 | — | — | US | disclosed |
| US-7309533-B2 | Substituted anthryl derivative and electroluminescence device using the same | CANON KABUSHIKI KAISHA (JP) | 2007-12-18 | — | — | US | disclosed |
| US-7173131-B2 | Anthryl derivative group substituted compound, and organic luminescent device making use of same | CANON KABUSHIKI KAISHA (JP) | 2007-02-06 | — | — | US | disclosed |
| US-20050099115-A1 | Substituted anthryl derivative and electoluminescence device using the same | CANON KABUSHIKI KAISHA (JP) | 2005-05-12 | — | — | US | disclosed |
| US-20040263067-A1 | Anthryl derivative group substituted compound, and organic luminescent device making use of same | CANON KABUSHIKI KAISHA (JP) | 2004-12-30 | — | — | US | disclosed |
| EP-0643682-A4 | PROCESSES AND INTERMEDIATES FOR THE PREPARATION OF 2-SUBSTITUTED BENZALDEHYDES. | SMITHKLINE BEECHAM CORP (US) | 1995-06-07 | — | — | EP | disclosed |
| EP-0643682-A1 | PROCESSES AND INTERMEDIATES FOR THE PREPARATION OF 2-SUBSTITUTED BENZALDEHYDES | SMITHKLINE BEECHAM CORPORATION (US) | 1995-03-22 | — | — | EP | disclosed |
| WO-1993019033-A1 | PROCESSES AND INTERMEDIATES FOR THE PREPARATION OF 2-SUBSTITUTED BENZALDEHYDES | SMITHKLINE BEECHAM CORPORATION (US) | 1993-09-30 | — | — | WO | disclosed |
| EP-0179953-B1 | MOLDING COMPOSITION | ARCO CHEMICAL TECHNOLOGY, INC. (US) | 1989-08-23 | — | — | EP | disclosed |
| EP-0134026-B1 | A METHOD OF MANUFACTURING A MACROMOLECULAR MATERIAL CONDUCTING CURRENT ON ITS SURFACE | POLSKA AKADEMIA NAUK CENTRUMBADAN MOLEKULARNYCH I MAKROMOLEKULARNYCH (PL) | 1987-10-14 | — | — | EP | disclosed |
| EP-0179953-A1 | Molding composition | ARCO CHEMICAL TECHNOLOGY, INC. (US) | 1986-05-07 | — | — | EP | disclosed |
| US-4485215-A | EPDM RUBBER, OLEFIN-ACRYLATE COPOLYMER, AROMATIC-NITRILE- MALEIMIDE TERPOLYMER | ATLANTIC RICHFIELD COMPANY (US) | 1984-11-27 | — | — | US | disclosed |
| US-4483966-A | CATALYTIC VAPOR PHASE POLYMERIZATION WITH COORIDNATION CATALYST | CHISSO CORPORATION (JP) | 1984-11-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220177476-A1 | Crystal Forms of (S)-4-(8-amino-3-(1-(but-2-ynoyl)-pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-n-(pyridin-2-yl)benzamide | ALB, NPY5R, PGA5 | LIPG 4717/4885TAAR1 3261/4885SLC6A2 1666/4885 |
| US-10640509-B2 | Pharmaceutical composition comprising a crystal form of (S)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-N-(pyridin-2-yl)benzamide for treating diffuse large B-cell lymphoma | MALT1, BCL6, BCL3 | LIPG 3252/4885TAAR1 4357/4885SLC6A2 2354/4885 |
| US-20190337949-A1 | Solid Forms and Formulations of Imidazopyrazine Compound | SLC5A2, IL5, NPY5R | LIPG 4858/4885TAAR1 3703/4885SLC6A2 1207/4885 |
| US-20170029428-A1 | Solid Forms and Formulations of Imidazopyrazine Compound | SLC5A2, IL5, NPY5R | LIPG 4858/4885TAAR1 3703/4885SLC6A2 1207/4885 |
| US-20050099115-A1 | Substituted anthryl derivative and electoluminescence device using the same | ALAD, ERAL1, LAGE3 | LIPG 166/4885TAAR1 1567/4885SLC6A2 4156/4885 |
| US-20040263067-A1 | Anthryl derivative group substituted compound, and organic luminescent device making use of same | ALAD, AAAS, NLRP1 | LIPG 2177/4885TAAR1 3063/4885SLC6A2 4432/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.